Katelyn O'Brien, PharmD, BCPS, CDCES, BC-ADM

Experts from the NEIAP 2026 Annual Forum share how pharmacists are driving hypertension, lipid, cardiorenal, obesity, and CDTM care as primary clinical decision-makers.

Katelyn O'Brien, PharmD, emphasizes sick-day management and preprocedure holds to lower euglycemic DKA risk with sodium-glucose cotransporter 2 (SGLT2) inhibitors.

Katelyn O'Brien, PharmD, says a shared view of cardio-kidney-metabolic syndrome lets pharmacists unify care across endocrinology, cardiology, and nephrology.

A panel of pharmacists and nurse practitioners discussed how interdisciplinary diabetes teams divide technology education, medication management, and follow-up care.

Katelyn O'Brien, PharmD, BCPS, CDCES, BC-ADM, discusses the New England Institute of Ambulatory Care Pharmacists (NEIAP) Annual Forum and previews key topics of discussion.

In addition to explaining how NEIAP has evolved over time, Katelyn O'Brien, PharmD, BCPS, CDCES, BC-ADM, previews key topics at the upcoming September meeting.

The selection of an agent for hyperglycemia management requires knowledge of both the efficacy and the potential adverse effects of each possible agent, so choosing the best therapy for any given patient can be complicated.